株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

びまん性大細胞型B細胞リンパ腫:世界の治験動向

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019

発行 GlobalData 商品コード 297511
出版日 ページ情報 英文 1115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
びまん性大細胞型B細胞リンパ腫:世界の治験動向 Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019
出版日: 2019年05月31日 ページ情報: 英文 1115 Pages
概要

当レポートでは、びまん性大細胞型B細胞リンパ腫に関する臨床研究の最新動向について分析し、疾患の概要を初め、主な先進国・新興国における治験の状況、地域および段階別の進行状況、被験者の募集状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験におけるびまん性大細胞型B細胞リンパ腫の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験におけるびまん性大細胞型B細胞リンパ腫の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

びまん性大細胞型B細胞リンパ腫治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

図表

List of Tables

  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

List of Figures

  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • GlobalData Methodology
目次
Product Code: GDHC5668CTIDB

GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2019" provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • List of Tables
  • List of Figures
  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
  • May 08, 2019: Innovative Cellular Therapeutics announces data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
  • May 07, 2019: Two clinical studies with IBI301, a biosimilar candidate to rituximab, met primary endpoints
  • May 03, 2019: IMV to provide updated data from phase 2 study evaluating DPX-Survivac in combination with Merck's Keytruda in DLBCL
  • May 01, 2019: Mixed results for new lymphoma therapy
  • Apr 10, 2019: Nordic Nanovector: safety review committee approves advancing to final dosing regimen in phase 1 trial of Betalutin in DLBCL
  • Apr 10, 2019: First patient enrolled in clinical trial for TREAKISYM rapid infusion liquid formulation
  • Apr 08, 2019: Completion of patient enrollment in phase 3 clinical trial of the anti-cancer drug Treakisym in relapsed/refractory diffuse large B-cell lymphoma
  • Apr 02, 2019: Kura Oncology identifies farnesylated proteins associated with CXCL12 expression, potential biomarker of clinical benefit from Tipifarnib in lymphoma indications
  • Mar 29, 2019: Kymera Therapeutics to present new preclinical data for its first-in-class oral IRAK4 degrader in MYD88-mutant lymphoma at late-breaking session of the American Association for Cancer Research Annual Meeting
  • Mar 28, 2019: Molecular Templates announces initiation of phase II monotherapy study of MT-3724 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients
  • Mar 07, 2019: MorphoSys provides updates on L-MIND and B-MIND clinical trials of MOR208 in relapsed/refractory DLBCL
  • Mar 05, 2019: EMA recommends Phase III study for VAL001
  • Feb 20, 2019: ADC Therapeutics announces first patient dosed in phase I clinical trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source
Back to Top